CMS updated recommendations for how drug manufacturers participating in the Medicaid Drug Rebate Program should calculate average manufacturer prices of brand and authorized generics, due to recent changes to the 2020 appropriations law and the 2019 Health Extenders Act. The notice, issued on Monday (May 18), will soon be followed by a regulation. The agency received a lot of questions from industry about manufacturer ownership arrangements and changes to the calculation of average manufacturer prices for generic and brand-name drugs...